Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker
Jan 8, 2025 · Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent …
Novo Nordisk Received an Upgrade from UBS for Its Ozempic …
Jan 8, 2025 · Despite Trump's tariff threat to Denmark and recent underwhelming trial data for Novo Nordisk's experimental obesity drug Carigsema, an upgrade came to Novo Nordisk from …
UBS Remains a Buy on Novo Nordisk (0QIU) | Markets Insider
5 days ago · UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s shares closed yesterday at …
UBS raises Novo Nordisk stock rating to buy, cuts price target
Jan 8, 2025 · On Wednesday, UBS analyst Jo Walton upgraded Novo Nordisk (NYSE: NVO) stock from a Sell to a Buy rating, though the price target was adjusted to DKK750.00 from the …
NVO Stock Up 3% as UBS Upgrades Company Rating From …
Jan 9, 2025 · Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.
Novo Nordisk A/S (NYSE:NVO) Upgraded to Buy at UBS Group
Jan 10, 2025 · Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at UBS Group from a “sell” rating to a “buy” rating in a research note issued to …
Novo Nordisk upgraded to Buy from Neutral at UBS, as …
Jan 8, 2025 · UBS analyst upgraded Novo Nordisk to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed” to continue to benefit from the high …
Novo Nordisk upgraded at UBS as analysts call CagriSema sell-off ...
Jan 8, 2025 · Investing.com - Novo Nordisk (CSE: NOVOb) remains the "most exciting growth story" in the European pharmaceutical sector and is in pole position to benefit from strong near …
Denmark's Novo Nordisk Rebounds Pre-Market On UBS Upgrade …
Jan 8, 2025 · Novo Nordisk shares climbed over 3% in Wednesday's pre-market trading as U.S. stock futures rebounded from a tech-driven selloff. The Danish pharmaceutical giant benefited …
UBS Upgrades Novo Nordisk A (NVO) - Nasdaq
Dec 23, 2024 · Fintel reports that on January 8, 2025, UBS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Sell to Buy. Analyst Price Forecast Suggests 61.15% Upside. As …